Empirical mono- versus combination antibiotic therapy in adult intensive care patients with severe sepsis – A systematic review with meta-analysis and trial sequential analysis

Journal of Infection

Volumn 74, Issue 4, 2017, Pages 331-344

  Sjövall, Fredrik ^a   Perner, Anders ^a   Hylander Møller, Morten ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Antibiotic; Combination; Human; Mortality; Sepsis; Septic shock

Indexed keywords

AMIKACIN; AMOXICILLIN; AZLOCILLIN; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CILASTATIN PLUS IMIPENEM; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; NETILMICIN; OFLOXACIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; APACHE; ARTIFICIAL VENTILATION; COMBINATION DRUG THERAPY; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE EFFECTIVENESS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; HUMAN; INTENSIVE CARE; LENGTH OF STAY; META ANALYSIS; MIXED INFECTION; MONOTHERAPY; MORTALITY RATE; PATIENT-REPORTED OUTCOME; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; WOUND INFECTION; ADULT; CLINICAL TRIAL (TOPIC); INTENSIVE CARE UNIT; MORTALITY; PROCEDURES;

ADULT; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CRITICAL CARE; DRUG THERAPY, COMBINATION; HUMANS; INTENSIVE CARE UNITS; SEPSIS; SHOCK, SEPTIC;

EID: 85008441297     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2016.11.013     Document Type: Review

References (40)

1. 1 Kaukonen, K.M., Bailey, M., Suzuki, S., Pilcher, D., Bellomo, R., Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA 311:13 (2014), 1308–1316.
2. 2 Mouncey, P.R., Osborn, T.M., Power, G.S., Harrison, D.A., Sadique, M.Z., Grieve, R.D., et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 372:14 (2015), 1301–1311.
3. 3 Angus, D.C., van der Poll, T., Severe sepsis and septic shock. N Engl J Med, 369(21), 2013, 2063.
4. 4 Tamma, P.D., Cosgrove, S.E., Maragakis, L.L., Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 25:3 (2012), 450–470.
5. 5 Dellinger, R.P., Levy, M.M., Rhodes, A., Annane, D., Gerlach, H., Opal, S.M., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:2 (2013), 165–228.
6. 6 Safdar, N., Handelsman, J., Maki, D.G., Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 4:8 (2004), 519–527.
7. 7 Paul, M., Soares-Weiser, K., Leibovici, L., Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ, 326(7399), 2003, 1111.
8. 8 Paul, M., Benuri-Silbiger, I., Soares-Weiser, K., Leibovici, L., Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ, 328(7441), 2004, 668.
9. 9 Chang, D.C., Wilson, S.E., Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections. Am J Surg 174:3 (1997), 284–290.
10. 10 Kumar, A., Safdar, N., Kethireddy, S., Chateau, D., A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med 38:8 (2010), 1651–1664.
11. 11 Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:7650 (2008), 924–926.
12. 12 Higgins, J.P.T., Green, S., Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011 [updated March 2011], Available from: www.cochrane-handbook.org.
13. 13 Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev, 4, 2015, 1.
14. 14 Ciani, O., Buyse, M., Garside, R., Pavey, T., Stein, K., Sterne, J.A., et al. Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study. BMJ, 346, 2013, f457.
15. 15 Guyatt, G.H., Oxman, A.D., Kunz, R., Atkins, D., Brozek, J., Vist, G., et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 64:4 (2011), 395–400.
16. 16 Brunkhorst, F.M., Oppert, M., Marx, G., Bloos, F., Ludewig, K., Putensen, C., et al. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA 307:22 (2012), 2390–2399.
17. 17 Heyland, D.K., Dodek, P., Muscedere, J., Day, A., Cook, D., Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 36:3 (2008), 737–744.
18. 18 Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21:11 (2002), 1539–1558.
19. 19 Wetterslev, J., Thorlund, K., Brok, J., Gluud, C., Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol, 9, 2009, 86.
20. 20 Sweeting, M.J., Sutton, A.J., Lambert, P.C., What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23:9 (2004), 1351–1375.
21. 21 Wetterslev, J., Thorlund, K., Brok, J., Gluud, C., Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 61:1 (2008), 64–75.
22. 22 Pogue, J., Yusuf, S., Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 351:9095 (1998), 47–52.
23. 23 Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315:7109 (1997), 629–634.
24. 24 Alvarez Lerma, F., Serious Infection Study G. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 13:1 (2001), 70–81.
25. 25 Christen, D., Buchmann, P., Geroulanos, S., Imipenem/cilastatin versus aminoglycoside plus amoxicillin plus clindamycin in the treatment of serious postoperative infections. Scand J Infect Dis Suppl 52 (1987), 11–14.
26. 26 Damas, P., Garweg, C., Monchi, M., Nys, M., Canivet, J.L., Ledoux, D., et al. Combination therapy versus monotherapy: a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia [ISRCTN31976779]. Crit Care (London, England), 10(2), 2006, R52.
27. 27 Jaspers, C.A., Kieft, H., Speelberg, B., Buiting, A., van Marwijk Kooij, M., Ruys, G.J., et al. Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients. Antimicrob Agents Chemother 42:5 (1998), 1233–1238.
28. 28 Kljucar, S., Heimesaat, M., von Pritzbuer, E., Olms, K., Ceftazidime with and without tobramycin versus azlocillin plus tobramycin in the therapy of bronchopulmonary infections in intensive care patients. Infection 15:Suppl. 4 (1987), S185–S191.
29. 29 Manhold, C., von Rolbicki, U., Brase, R., Timm, J., von Pritzbuer, E., Heimesaat, M., et al. Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study. Intensive Care Med 24:12 (1998), 1327–1330.
30. 30 Mouton, Y., Deboscker, Y., Bazin, C., Fourrier, F., Moulront, S., Philippon, A., et al. Prospective, randomized, controlled study of imipenem-cilastatin versus cefotaxime-amikacin in the treatment of lower respiratory tract infection and septicemia at intensive care units. Presse Med 19:13 (1990), 607–612.
31. 31 Leroy, O., Saux, P., Bedos, J.P., Caulin, E., Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 128:1 (2005), 172–183.
32. 32 Polk, H.C. Jr., Livingston, D.H., Fry, D.E., Malangoni, M.A., Fabian, T., Trachtenberg, L.S., et al. Treatment of pneumonia in mechanically ventilated trauma patients. Results of a prospective trial. Arch Surg 132:10 (1997), 1086–1092.
33. 33 Schentag, J.J., Wels, P.B., Reitberg, D.P., Walczak, P., Van Tyle, J.H., Lascola, R.J., A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin in abdominal sepsis. Ann Surg 198:1 (1983), 35–41.
34. 34 Geroulanos, S., Stern, A., Christen, D., Buchmann, P., Antimicrobial management of postoperative infections in abdominal surgery: single or combination regimen?. Clin Ther 12:Suppl. B (1990), 34–42.
35. 35 Savovic, J., Jones, H.E., Altman, D.G., Harris, R.J., Juni, P., Pildal, J., et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 157:6 (2012), 429–438.
36. 36 Paul, M., Shani, V., Muchtar, E., Kariv, G., Robenshtok, E., Leibovici, L., Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 54:11 (2010), 4851–4863.
37. 37 Paul, M., Lador, A., Grozinsky-Glasberg, S., Leibovici, L., Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev, 1, 2014, CD003344.
38. 38 Bowers, D.R., Liew, Y.X., Lye, D.C., Kwa, A.L., Hsu, L.Y., Tam, V.H., Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 57:3 (2013), 1270–1274.
39. 39 Thorlund, K., Devereaux, P.J., Wetterslev, J., Guyatt, G., Ioannidis, J.P., Thabane, L., et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. Int J Epidemiol 38:1 (2009), 276–286.
40. 40 Kumar, A., Zarychanski, R., Light, B., Parrillo, J., Maki, D., Simon, D., et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Critical Care Med 38:9 (2010), 1773–1785.